As revealed by Fan et al., by blocking CTLA-4 and participating in ICOS with tumor cell vaccine, engineered expression of ICOS ligand resulted in a qualitative and quantitative increase in the anti-tumor immune response in mice that had developed prostate cancer and melanoma significantly promoted rejection [38]. The gene discussed is ICOS; the disease is prostate carcinoma.